Welcome to our dedicated page for 23Andme Holding Co news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding Co stock.
News for 23andMe Holding Co. (Nasdaq: ME), now renamed Chrome Holding Co. in SEC filings, centers on its evolution as a genetics-led consumer healthcare, biotechnology, and research company and on significant corporate restructuring events. Press releases describe 23andMe as a human genetics company with a mission to help people access, understand, and benefit from the human genome, and as a genetics-led consumer healthcare and research or biopharmaceutical company empowering a healthier future.
Visitors to this news feed can review updates on Chapter 11 proceedings, including the company’s voluntary filing in the U.S. Bankruptcy Court for the Eastern District of Missouri, court approvals of first-day motions, and the launch of a court-supervised sale process. Releases detail the company’s efforts to obtain debtor-in-possession financing, sell substantially all of its assets, and address operational, financial, and legal challenges, as well as subsequent SEC reports on the approved and completed sale of assets to 23andMe Research Institute.
The news stream also covers strategic and operational developments such as the exploration of strategic alternatives, workforce reductions, discontinuation of the Therapeutics operating segment, and restructuring initiatives aimed at cost reductions. Financial results announcements provide context on revenue trends, changes in operating expenses, and management’s previously stated concerns about liquidity and ability to continue as a going concern before the Chapter 11 filing.
In addition, 23andMe’s news highlights product and research updates, including new genetic reports for 23andMe+ Premium members on topics such as osteoporosis and homocysteine (MTHFR-related) levels, the launch of Discover23 for biopharma collaborators, and collaborations with partners like Mirador Therapeutics. Telehealth and preventive health initiatives, such as GLP-1 weight loss offerings on the Lemonaid Health platform and a comprehensive longevity service, also appear in company communications.
For investors and observers following ME-related developments, this page aggregates company-issued news on genetics products, research collaborations, telehealth services, financial performance, governance changes, and the ongoing Chapter 11 restructuring and asset sale process.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, affecting 7 million users. Hackers specifically targeted Jewish and Chinese customers, leaking personal genetic information including names and addresses, which was then sold on the dark web. Despite knowing the specific targeting, 23andMe did not inform the affected customers in their December notification. A class action lawsuit has been filed, accusing the company of concealing the extent of the breach and the specific targeting of Jewish and Chinese users. The leaked data has raised significant safety concerns, especially for Chinese customers due to potential government tracking.
On May 17, 2024, 23andMe (NASDAQ:ME) disclosed a data breach from December 2023 that affected approximately 7 million users. Hackers specifically targeted Jewish and Chinese customers, selling their personal genetic information on the dark web. A class action lawsuit alleges that 23andMe concealed these details when informing customers about the breach. The targeted data included genetic heritage, names, and addresses. The breach has raised safety concerns, particularly for Chinese customers worried about government surveillance. The lawsuit claims that 23andMe has yet to notify affected users about the specific targeting and the sale of their data online.
On May 16, 2024, 23andMe (NASDAQ:ME) revealed that hackers breached their systems in December 2023, affecting 7 million users. The hack specifically targeted Jewish and Chinese customers, compiling their personal genetic data, which was sold on the dark web. A class action lawsuit alleges that 23andMe concealed these details from those affected. The hacker leaked lists of over 1 million Jewish and 350,000 Chinese customers, generating significant interest on the dark web. 23andMe initially attributed the breach to recycled login credentials and delayed the announcement until December without mentioning the specific targeting or data sale. Law firm Levi & Korsinsky is investigating potential compensation for affected users.
23andMe (NASDAQ: ME) experienced a major data breach in December 2023, affecting 7 million users. Hackers targeted Jewish and Chinese customers, extracting and selling their genetic information on the dark web. The breach was disclosed in December 2023, but the specific targeting was concealed until a recent class action complaint. Hackers leaked lists of over 1 million Jewish and 350,000 Chinese customers, raising serious safety concerns. The company has yet to inform all affected users. Legal action is underway, and affected individuals in certain states are urged to seek compensation.
Lemonaid Health, a subsidiary of 23andMe Holding Co. (Nasdaq: ME), announces its collaboration with Petros Pharmaceuticals (Nasdaq: PTPI) to offer STENDRA® (avanafil), a prescription ED medication, through its telehealth platform. This medication acts within 15 minutes and will be available at improved pricing. With an estimated one in 10 men experiencing ED, this initiative aims to enhance medication accessibility and affordability. Lemonaid Health, which has treated over 200,000 ED patients, provides medication delivery across the U.S. from a 50-state licensed pharmacy. The collaboration aims to offer patients better access to brand-name medications.
23andMe (NASDAQ:ME) faced a data breach affecting 7 million users, with hackers targeting Jewish and Chinese customers and selling their genetic information on the dark web. The breach compromised personal data, posing potential risks to affected customers. 23andMe failed to disclose the specific targeting of these groups, leading to legal action and concerns over customer safety.
23andMe Holding Co. (Nasdaq: ME) will announce its financial results for Q4 and FY2024 on May 23, 2024. The company aims to discuss its business progress during a webcast at 4:30 p.m. Eastern Time on the same day. Shareholders can participate in the Q&A session by submitting questions in advance. The webcast link will be available at https://investors.23andme.com/news-events/events-presentations.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting 7 million users. The hackers specifically targeted Jewish and Chinese customers, selling their genetic information on the dark web. The breach poses a significant threat to affected customers, with 23andMe failing to disclose the extent of the breach and the specific targeting of Jewish and Chinese users. Levi & Korsinsky, LLP is investigating potential compensation for affected individuals.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting around 7 million users, particularly Jewish and Chinese customers. The hackers compiled genetic heritage, names, and addresses of these customers, selling the data on the dark web. The breach poses risks to affected individuals, especially from the Chinese government's tracking. 23andMe failed to inform compromised customers of the breach or the specific targeting of Jewish and Chinese individuals. Levi & Korsinsky is investigating potential compensation for affected parties.
FAQ
What is the current stock price of 23Andme Holding Co (ME)?
What is the market cap of 23Andme Holding Co (ME)?
